1Baynes, JW, Watkins, NG, Fisher, CI, et al. (1989) The Amadori product on protein: structure and reactions. Prog Clin Biol Res 304, 43–67.
2Bry, L, Chen, PC & Sacks, DB (2001) Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 47, 153–163.
3Sing, R, Barden, A, Mori, T, et al. (2001) Advanced glycation end products: a review. Diabetologia 44, 129–146.
4Kumar, MS, Reddy, PY, Kumar, PA, et al. (2004) Effect of dicarbonyl-induced browning on α-crystallin chaperone-like activity: physiological significance and caveats of in vitro aggregation assays. Biochem J 379, 273–282.
5Kumar, MS, Mrudula, T, Mitra, N, et al. (2004) Enhanced proteolytic degradation and altered ATP binding of methylglyoxal modified α-crystallin. Exp Eye Res 79, 577–583.
6Vlassara, H (1996) Advanced glycation end products and atherosclerosis. Ann Med 28, 419–426.
7Shuvaev, VV, Laffont, I, Serot, JM, et al. (2001) Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 22, 397–402.
8Morena, M, Cristol, JP, Senecal, L, et al. (2002) Oxidative stress in hemodialysis patients: is NADPH oxidase complex the culprit? Kidney Int Suppl., 80, 109–114.
9Brownlee, M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46, 223–234.
10Yan, SD, Schmidt, AM, Anderson, GM, et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269, 9889–9897.
11Mrudula, T, Suryanarayana, P, Srinivas, PNBS, et al. (2007) Effect of curcumin on VEGF expression in diabetic retina. Biochem Biophys Res Commun 361, 528–532.
12Bengmark, S (2007) Advanced glycation and lipoxidation end products – amplifiers of inflammation: the role of food. JPEN J Parenter Enteral Nutr 31, 430–440.
13Edelstein, D & Brownlee, M (1992) Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41, 26–29.
14Freedman, BI, Wuerth, JP, Cartwright, K, et al. (1999) Design and baseline characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20, 493–510.
15Stitt, A, Gardiner, TA, Alderson, NL, et al. (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51, 2826–2832.
16Vasan, S, Zhang, X, Zhang, X, et al. (1996) An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382, 275–278.
17Swanston-Flatt, SK, Flatt, PR, Day, C, et al. (1991) Traditional dietary adjuncts for the treatment of diabetes mellitus. Proc Nutr Soc 50, 641–651.
18Grover, JK, Yadav, S & Vats, V (2002) Medicinal plants of India with anti diabetic potentials. J Ethanopharmacol 81, 81–100.
19Oubré, AY, Carlson, TJ, King, SR, et al. (1997) From plant to patient; an ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia 40, 614–617.
20Bailey, CJ & Day, C (1989) Traditional plant medicines as treatments for diabetes. Diabetes Care 12, 553–564.
21Makita, Z, Vlassara, H, Cerami, A, et al. (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267, 5133–5138.
22Kumar, PA, Reddy, PY, Srinivas, PNBS, et al. (2008) Delay of diabetic cataract in rats by antiglycating potential of cumin through modulation of α-crystallin chaperone activity, J Nutr Biochem .
23Kumar, PA, Kumar, MS & Reddy, GB (2007) Effect of glycation on α-crystallin structure and chaperone-like function. Biochem J 408, 251–258.
24Uchida, K, Kanematsu, M, Sakai, K, et al. (1998) Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A 95, 4882–4887.
25Gabir, MM, Hanson, RL & Dabelea, D (2000) Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 23, 1113–1118.
26Brownlee, M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820.
27Mohan, V, Sandeep, S, Deepa, R, et al. (2007) Epidemiology of type 2 diabetes. Indian J Med Res 125, 217–230.
28King, H, Aubert, RE & Herman, WH (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21, 1414–1431.
29Zimmet, PZ (1999) Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 42, 499–518.
30Zimmet, PZ (1999) Diabetes epidemiology as a tool to trigger diabetes research and care. Erratum. Diabetologia 42, 1032.
31Huebschmann, AG, Regensteiner, JG, Vlassara, H, et al. (2006) Diabetes and advanced glycoxidation end products. Diabetes Care 29, 1420–1432.
32Strippoli, GF, et al. Di Paolo, S & Cincione, R (2003) Clinical and therapeutic aspects of diabetic nephropathy. J Nephrol 16, 487–499.
33Ahmad, MS & Ahmed, N (2006) Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications. J Nutr 136, Suppl. 3, 796S–799S.
34Nakagawa, T, Yokozawa, T, Terasawa, K, et al. (2002) Protective activity of green tea against free radical- and glucose-mediated protein damage. J Agric Food Chem 50, 2418–2422.
35Kiho, T, Usui, S, Hirano, K, et al. (2002) Tomato paste fraction inhibiting the formation of advanced glycation end-products. Biosci Biotechnol Biochem 68, 200–205.
36Cai, Y, Luo, Q, Sun, M, et al. (2004) Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sci 74, 2157–2184.
37Balasundram, N, Sundram, K & Samman, S (2006) Phenolic compounds in plants and agri-industrial by-products: antioxidant activity, occurrence, and potential uses. Food Chem 99, 191–203.
38Saraswat, M, Reddy, PY, Suryanarayana, P, et al. (2008) Inhibition of protein glycation by dietary agents: implications in the prevention of diabetic occular complications. Invest Ophthalmol Vis Sci 49, . Available at www.arvo.org.
39Suryanarayana, P, Saraswat, M, Mrudula, T, et al. (2005) Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci 46, 2092–2099.
40Suryanarayana, P, Saraswat, M, Petrash, JM, et al. (2007) Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. Mol Vision 13, 1291–1297.
41Raskin, P & Rosenstock, J (1987) Aldose reductase inhibitors and diabetic complications. Am J Med 83, 298–306.